

PMC SCIENCE AND PUBLIC POLICY COMMITTEES MEETING AGENDA

December 2, 12:00 – 2:00 p.m. ET

Link to webinar:

<https://permedcoalition.webex.com/permedcoalition/onstage/g.php?MTID=ed1d61d185cb326639e89fbe31608e2ea>

(passcode: pmc123)

Dial 202-800-9984 and enter meeting ID 825756.

Note: You will be muted upon entry. Please dial 4* to unmute your line.

12:00 p.m. ET **Welcome & Introduction**

Edward Abrahams

President

Personalized Medicine Coalition

12:05 p.m. ET **Dynamic Scoring and Personalized Medicine**

- **Douglas Holtz-Eakin, Ph.D.**

President

American Action Forum

12:35 p.m. ET **Business Meeting**

Cynthia A. Bens

Senior Vice President, Public Policy

Personalized Medicine Coalition

- **Public Policy Updates**

- **Congressional Activities**

- [Congressional Personalized Medicine Caucus](#)

- *Congress and Personalized Medicine: The Perspectives of the Co-Chairs of the Personalized Medicine Caucus*

- *21st Century Cures 2.0* (Reps. DeGette and Upton [press release](#))

- PMC [comment letter](#) (July 16, 2021)

- *Precision Medicine Answers for Kids Today Act* (Reps. Swalwell, Peters and Emmer [press release](#))

(continued)

- FY 2022 appropriations for FDA and NIH
 - PMC [outside witness testimonies](#) (May 2021)
 - Ad Hoc Group [Sign-on Letter](#) (November 15, 2021)
- **Regulation**
 - Nomination of Dr. Robert Califf as FDA Commissioner
 - Friends of Cancer Research [Sign-on Letter](#) (December 1, 2021)
 - User fee program reauthorization
 - PMC's [remarks](#) during FDA's *Public Workshop on the Seventh Reauthorization of the Prescription Drug User Fee Act* (September 28, 2021)
 - PMC [comment letter](#) on *Medical Device User Fee Amendments for Fiscal Years 2023 Through 2027* (November 27, 2020)
 - STRIPE: A Collaborative Community in Pharmacogenomics ([website](#))
- **Coverage and Reimbursement**
 - Directions for CMMI's *Oncology Care First Model*
 - Proposed rescission of CMS' *Most Favored Nation (MFN) Model*
 - PMC [comment letter](#) (October 12, 2021)
 - Withdrawal of CMS' *Medicare Coverage of Innovative Technology (MCIT) and Definition of "Reasonable and Necessary" (R&N) final rule*
 - PMC [comment letter](#) (October 15, 2021)
 - National Government Services' proposed local coverage determination on *Genomic Sequence Analysis Panels in the Treatment of Solid Organ Neoplasms*
 - PMC [comment letter](#) (November 13, 2021)
- **Evidence-Based Medicine**
 - National Committee for Quality Assurance's proposed changes to colorectal cancer screening measure
 - PMC [comment letter](#) (October 21, 2021)
- **Working Group Updates**
 - Pharmaceutical & Diagnostics Working Group
 - Patient Advocacy Organization Working Group

(continued)

Daryl Pritchard, Ph.D.

Senior Vice President, Science Policy
Personalized Medicine Coalition

- **Science Policy Updates**
 - [*A Research Program for Advancing Personalized Medicine in 2022: An Overview of Initiatives to Evaluate Progress in Health Care, Assess Clinical and Economic Value, and Examine Clinical Integration Strategies*](#)
 - Research Program Study No. 9: "Addressing Disparities and Improving Health Equity in Research Advancing Personalized Medicine"
 - Research Program Study No. 3: "Payer Perspectives and Policies on Personalized Medicine: A Landscape Analysis"
 - [Project Overview](#)
 - **Working Group Updates**
 - Pharmacogenomics Working Group
 - Health Care Working Group

David Davenport

Manager, Public Policy
Personalized Medicine Coalition

- PMC's [2022 Policy Agenda](#)

1:50 p.m. ET New Business

2:00 p.m. ET Conclusion